Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis.
about
Endoplasmic Reticulum Stress in the Diabetic Kidney, the Good, the Bad and the UglyDrug-induced glomerular disease: direct cellular injury.From rapalogs to anti-aging formula.A 12-month single arm pilot study to evaluate the efficacy and safety of sirolimus in combination with tacrolimus in kidney transplant recipients at high immunologic riskEfficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant RecipientsTwenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy.The need for minimization strategies: current problems of immunosuppression.Identifying endpoints to predict the influence of immunosuppression on long-term kidney graft survival.Treating posttransplantation diabetes mellitus.Safety of mTOR inhibitors in adult solid organ transplantation.New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation.Spectrum of anemia after kidney transplantation: pathophysiology and therapeutic implications.Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients.Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial.Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation.Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia.[Immunosuppression and its use in kidney transplantation].Eight-year results of the Spiesser study, a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation.Lipid lowering in renal disease.Efficacy and safety of early tacrolimus conversion to sirolimus after kidney transplantation: Long-term results of a prospective randomized study.mTOR Inhibition: Reduced Insulin Secretion and Sensitivity in a Rat Model of Metabolic Syndrome.Successful management of steroid-resistant vascular tumors associated with the Kasabach-Merritt phenomenon using sirolimus.Switch to an everolimus-facilitated cyclosporine A sparing immunosuppression improves glycemic control in selected kidney transplant recipients.Improved Fetal Hemoglobin With mTOR Inhibitor-Based Immunosuppression in a Kidney Transplant Recipient With Sickle Cell Disease.Management Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review.Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus.Serum Magnesium after Kidney Transplantation: A Systematic Review.Overview of Cellular Transplantation in Diabetes Mellitus: Focus on the Metabolic Outcome
P2860
Q26799567-CC2B911F-3727-422B-A6BF-30F0C1ACCBE7Q27692666-659ADA64-8359-41C7-80F9-AF5EDA403DA5Q33829205-91A594AB-779F-4806-8004-E4CFC09B07BCQ35649082-3CB9845D-BAFE-4233-A1D2-7C40C95FF511Q35788609-FFB0792F-7BC3-4165-A592-BF3A9ED7B79CQ36297539-C09BC7FB-8AE7-46C0-8332-52CF04F3845EQ38370826-A4CB1DC7-A85C-437E-9BD6-2BD82770332DQ38429887-1CD3AB86-309F-4A35-BF0E-53F9390BE2E9Q38441421-E046EEF6-7C78-4DB8-925F-03B8B4C2CBCDQ38669190-FFF4C63D-56FC-48CA-BB19-96D21FCA67F3Q38711763-F82C9E07-D888-4D55-8EA4-AE0B4266A0FEQ38900551-F51E38AD-391B-4773-A54D-6670F02D89ACQ38914374-375E09FD-5A32-41CC-9853-5ABD723C44EAQ38962103-92D04FCA-A22E-4A1D-B951-FAE5D83778F1Q39573385-94E18102-5163-49DE-936A-16A715BC4F7CQ40176051-EA94639A-41D6-4F3B-8080-501A5E22D08BQ40540152-ED4F54DC-BA3B-4EBF-A538-AD53FB1FB94DQ40907143-7412AE27-2C3E-4608-95F2-743F4E070A4AQ40956126-091EDBAF-B6FF-4102-85C0-92B8F51BBC81Q41472979-BB5A17D2-03A1-458D-A09C-AD4D88A46F6AQ41690923-9519EF20-E727-46A9-A033-DF71C4A1A58EQ42328635-68435750-110E-4A47-B179-7404509B9DA2Q42418240-244D2EB9-A6F7-447E-8629-D989306F7F4FQ48197793-11B8B619-4C1B-4E79-A6DF-4111D4881C66Q48329048-76DA470C-4A81-42B9-B70F-843BC1617544Q51836741-5FB2EAC4-07E2-42E5-A730-4861B7BB5ED2Q52603541-EDBFA646-7CEE-4C3B-BA54-7CB673BC035EQ53425824-1DDD0AA9-9ABC-4444-9DCB-6304B963CA4AQ55447877-3B7956B3-1797-43BC-B82F-B5E9CA5C6054Q59101873-3C6BB327-714E-4090-950F-DAED309F44D0
P2860
Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Risk of metabolic complication ...... atic review and meta-analysis.
@en
type
label
Risk of metabolic complication ...... atic review and meta-analysis.
@en
prefLabel
Risk of metabolic complication ...... atic review and meta-analysis.
@en
P2093
P2860
P356
P1476
Risk of metabolic complication ...... atic review and meta-analysis.
@en
P2093
L V Riella
N Murakami
T Funakoshi
P2860
P304
P356
10.1111/AJT.12852
P407
P577
2014-08-21T00:00:00Z